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Abstract
The aim of the study is to develop a method for forecasting the indicators for drug reimbursement to patients with cardiovascular 
diseases (CVD) in Ukraine within the framework of the government program “Available medicines”. 
Materials and methods: materials of the State Statistics Service of Ukraine and medical records of patients with CVD, who 
were prescribed with medicines according to the government program, were used in the study. 
Results: according to the method proposed for forecasting the volume of drug reimbursement to patients with CVD under the 
government program it has been found that Enalapril has the highest indicator – 10916.4 USD thousand in 2019 and 10736.8 USD thou-
sand in 2020. Clopidogrel takes the second position – 12108.13 USD thousand and 11908.24 USD thousand, while Amlodipine occupies 
the third position – 9105.60 USD thousand and 8955.28 USD thousand. 
Among the medicines not included in the government program, but prescribed rather frequently the largest forecasting amount 
required for reimbursement (in case of inclusion in the program) is 18910.55 USD thousand in 2019 and 18598.36 USD thousand in 2020 
for Magnicor, and the least amount is 444.55 USD thousand and 437.22 USD thousand for Acetylsalicylic acid, respectively. 
Conclusions. The government program to provide patients with effective and affordable medicines has a significant impact 
on reforming the healthcare system of Ukraine. The study conducted can be used to expand the government program in the process of 
formation and distribution of budget funds.
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1. Introduction
Cardiovascular diseases (CVD) hold a leading place in the world among other nosology’s 
by the number of deaths of the working-age population. In the field of healthcare of the leading 
countries of the world, the government programs for drug reimbursement are increasingly intro-
duced to improve the availability and quality of medical and pharmaceutical care to all segments 
of the population [1–3]. Since 2012, government projects and programs to increase the availability 
of pharmaceutical care to all segments of the population have been implemented in the healthcare 
of Ukraine. In 2017, the government program “Available medicines” was introduced with the aim 
of providing patients with life-saving necessary medicines for the treatment of nosologies, such 
as CVD, asthma and type II diabetes [3]. In the same year, thanks to the support of Management 
Sciences for Health (MSH), the project “Safe, available and effective medicines for Ukrainians” 
(SAFEMed) began its work in Ukraine. Its main goal is to improve the financing mechanisms of 
the national healthcare system [4]. 
As practice has shown, the pharmacotherapy of CVD is quite expensive and long due to the 
peculiarity of the disease course and the presence of concomitant nosologies in a patient. Therefore, 
the rational use of budgetary funds is one of the main components for further development of the 
healthcare system. 
2. Aim of the research
The aim of our study was to develop a method for predicting the indicators for drug reim-
bursement to patients with CVD in Ukraine within the framework of the government program 
“Available medicines”.
3.Materials and methods
Materials from the official Express issues formed by the State Statistics Service of 
Ukraine (within 2013–2018); medical records of patients with CVD, who were prescribed 
medicines according to the government program for reimbursement; the data of our prelimi-
nary pharmacoeconomical analysis of treatment regimens of patients with CVD were used in 
the study [5–7]. Statistical, analytical, mathematical methods and the method of generaliza-
tion of scientific information were applied in the work. The method of the study is presented 
in Fig. 1.
Fig. 1. The research method for predicting the indicators for drug reimbursement to patients with 
cardiovascular diseases 
Despite the fact that CVD have a significant variation in morbidity indicators their ranking 
by regions of Ukraine was conducted according to three groups (Table 1).
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Table 1
The results of ranking the Ukrainian regions by the level of CVD morbidity in 2018
Group Morbidity per 100 thousand people Regions
І 1965–3622 Khersonska, Cherkaska, Zaporizka, Volynska regions
ІІ 3623–5280
City of Kyiv; Chernihivska, Chernivetska, Khmelnytska, Kharkivska, Ternopil-
ska, Sumska, Rivnenska, Poltavska, Odeska, Lvivska, Kirovohradska, Kyivska, 
Zakarpatska, Zhytomyrska, Vinnytska regions
ІІІ 5281–6938 Mykolaivska, Ivano-Frankivska, Dnipropetrovska regions
The first group contained regions with low morbidity, for which fluctuations in the incidence 
were within 1965–3622 cases; in the second group there were regions with an average incidence 
of 3623–5280 cases, and the third group comprised regions of Ukraine with a high incidence of 
CVD, which incidence rate ranged from 5281 to 6938 cases per 100 thousand population. In total, 
the first and second group included 20 regions, which was 86.95 % of the total number of territory 
administration units. In the third group there were three regions with the share of 13.05 %. It should 
be noted that they are industrial-agricultural and port regions of Ukraine, their highest incidence 
rate is characterized by inadequate indicators of quality of life. 
For calculations, the program STATISTICA was used for each region of the country, and the 
regression loglinear model and the determination coefficient were calculated. Prognosis of indica-
tors of prevalence of patients with CVD in territory administration units of the country was done 
for 2019–2020 (per 100 thousand of the population).
4. Result
The low level of state funding, inefficient allocation of budget funds between regions of the 
country and their spending are the main problems of development of the healthcare system of Ukraine 
[8]. As a result, patients have to pay most of the money for the treatment from their family budget. 
In this regard, the solution of these problems is a priority in further development and reforming of 
the national healthcare in Ukraine. [9]. Thus, the proper access of all segments of the population to 
timely, high-quality and affordable medical and pharmaceutical care is possible only with reasonable 
calculations of indicators of drug reimbursement, in particular under the government programs [10].
According to the method proposed for forecasting the volume of drug reimbursement to pa-
tients with CVD under the government program it has been found that Сlopidogrel has the highest 
indicator – 12108.13 USD thousand in 2019 and 11908.24 USD thousand in 2020 (Table 2).
Enalapril takes the second position – 10916.39 USD thousand and 10736.18 USD thousand, 
while Amlodipine occupies the third position – 9105.60 USD thousand and 8955281.42 USD thou-
sand. Among the medicines not included in the government program, but prescribed rather fre-
quently the largest forecasting amount required for reimbursement (in case of inclusion in the 
program) is 18910.55 USD thousand in 2019 and 18598.36 USD thousand in 2020 for Magnicor, 
and the least amount is 444.55 USD thousand and 437.22 USD thousand for Acetylsalicylic acid, 
respectively. At the next stage, drug reimbursement for patients with CVD in the regions of the 
country for 2019 and 2020 was calculated (Table 3). The regions of the country were located ac-
cording to the ranking, which is shown in Table 1.
Thus, for 2019 and 2020, the highest indicators among medicines recommended for inclusion 
in the program under condition of its expansion are observed in the Mykolaivska region for Magnicor, 
75 mg, No. 100, – 1338.71 USD thousand and 1348.71 USD thousand, respectively, while the lowest 
indicators are in the Khersonska region for Acetylsalicylic acid, 500 mg, No.10, – 6.70 USD thousand 
and 4.20 USD thousand, respectively. Among medicines included in the program “Available medicines” 
the highest indicator for reimbursement in 2019 is for Clopidogrel, 75 mg, No. 90 – 857.15 USD thou-
sand in the Mykolaivska region, and the lowest indicator is for Hydrochlorothiazide, 25 mg, No. 20 – 
39.71 USD thousand in the Khersonska region. In 2020 the highest indicator is in the Mykolaivska 
region for Clopidogrel, 75 mg, No.90 – 863.56 USD thousand, while the lowest indicator is for Hy-
drochlorothiazide, 25 mg, No.20 – 25.29 USD thousand in the Khersonska region, respectively. It 
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should be noted that there is a relationship between the results of ranking the regions of Ukraine by 
the incidence of CVD and the volume of the forecasting amount of compensation.
Table 2
The forecasting indicators of reimbursement recommended for patients with CVD
Drug name / 
Dosage 
Intensity of 
drug prescrip-
tion (absolute 
indicator)
Intensity of 
drug prescrip-
tion, % 
К
і
of intensity of 
drug prescrip-
tion
The average 
cost of treat-
ment , USD
Theforecasting 
amount of drug 
reimbursement 
for 2019,  
USD thousand
Theforecasting 
amount of drug 
reimbursement 
for 2020,  
USD thousand
Clopidogrel, 75 
mg, No. 90 413 5.26 0.347 353.45 12108.13 11908.24
Magnicor, 75 
mg, No. 100 870 11.08 0.731 262.04 18910.55 18598.36
Simvastatin, 40 
mg, No. 28 191 2.43 0.161 226.62 3601.97 3542.50
Enalapril, 20 
mg, No.20 526 6.7 0.442 250.17 10916.39 10736.18
Amlodipine, 5 
mg, No. 30 484 6.16 0.407 226.62 9105.60 8955.28
Bisoprolol, 5 mg, 
No. 50 184 2.34 0.155 226.54 3466.62 3409.39
Verapamil, 40 
mg, No. 20 160 2.04 0.134 228.50 3022.77 2972.87
Acetylsalicylic 
acid, 500 mg, 
No. 10
21 0.27 0.018 250.17 444.55 437.22
Atenolol, 100 
mg, No. 20 181 2.29 0.151 226.96 3383.42 3327.57
Hydrochloro-
thiazide, 25 mg, 
No.20
143 1.82 0.12 223.33 2645.79 2602.11
Note: the USD exchange rate as of 28.11.2018 – 1 USD=28,11 UAH 
Thus, the highest forecasting amount of compensation was determined in the Mykolaivska re-
gion, which was referred in the process of ranking to the third group of regions with a high incidence 
of the population, and the smallest figures of the estimated amounts of compensation were observed 
in the Khersonska region referred to the first group – regions with low morbidity of the population. 
The overall average indicators of drug reimbursement in Ukraine are 67605.8 USD thousand for 2019, 
and 65604.2 USD thousand for 2020. The overall average indicator of forecasting drug reimburse-
ment in the regions of the country per one patient was also calculated and ranked in three groups 
(Tables 4, 5). 
In particular, for 2019 the first group contained such medicines as Acetylsalicylic acid, Hy-
drochlorothiazide, Verapamil, Atenolol, Enalapril, Simvastatin in all regions, Amlodipine was only 
by the indicator in the Khersonska, Kharkivska and Vinnytska regions, Enalapril and Clopidogrel 
were only by the indicator in the Khersonska region. In the second group there were Amlodipine, 
Clopidogrel, Enalapril in all regions except those referred to the first group and Magnicor was only 
by the indicators in the Khersonska and Vinnytska regions. Magnicor was in the third group in all 
regions except the Khersonska and Vinnytskaregions. For 2020 the first group contained such med-
icines as Acetylsalicylic acid, Hydrochlorothiazide. Verapamil, Atenolol, Enalapril, Simvastatin, 
while Amlodipine was included in this group in the Khersonska, Vinnytska, Cherkaska regions by 
the indicators. Enalapril, Clopidogrel, Magnicor were also included in the first group by the indica-
tor of drug consumption per one patient in the Khersonska region. 
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Table 3
The forecasting amount of drug reimbursement recommended for the treatment of CVD in the regions of 
the country for 2019 and 2020
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
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V
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The second group contained such medicines as Amlodipine, Clopidogrel, Enalapril in all re-
gions except those referred to the first group and Magnicor by the indicator in the Vinnytska region. 
Thus, Magnicor was in the third group as in 2019. Therefore, in 2019 and 2020 Acetylsalicylic acid, 
in case of its inclusion in the program, has the lowest forecasting overall average indicator of drug 
reimbursement in the Khersonska region – 1.89 and 1.36 USD per one patient. In case of inclusion 
of the drug in the program In case of its inclusion in the program Magnicor has also the highest 
indicator – 225.36 USD per one patient in 2019 and 210.99 USD in 2020. 
Continuation of Table 3
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Table 4
The overall average indicators of forecasting drug reimbursement in the regions of Ukraine per one patient 
in 2019 (USD)
Drug 
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City of Kyiv 4.44* 26.42 30.18 33.78 34.61 35.96 90.92 109.00 120.90 188.82
Chernihivska 4.09 24.37 27.84 31.16 31.93 33.17 83.86 100.53 111.51 174.15
Chernivetska 3.86 22.98 26.25 29.38 30.10 31.28 79.07 94.80 105.15 164.22
Cherkaska 3.85 22.91 26.18 29.30 30.02 31.19 78.85 94.53 104.85 163.76
Khmelnytska 4.24 25.23 28.83 32.27 33.06 34.35 86.84 104.10 115.47 180.34
Khersonska 1.89 11.24 12.84 14.37 14.72 15.30 38.67 46.36 51.42 80.31
Kharkivska 3.73 22.19 25.35 28.37 29.07 30.21 76.36 91.55 101.54 158.59
Ternopilska 4.63 27.54 31.47 35.22 36.09 37.49 94.79 113.63 126.04 196.85
Sumska 4.40 26.18 29.91 33.47 34.30 35.64 90.09 108.00 119.80 187.10
Rivnenska 4.06 24.16 27.60 30.89 31.65 32.89 83.14 99.68 110.56 172.67
Mykolaivska 5.30 31.53 36.02 40.32 41.31 42.92 108.51 130.09 144.29 225.36
Odeska 4.00 23.80 27.19 30.43 31.18 32.40 81.90 98.19 108.91 170.09
Poltavska 4.55 27.09 30.95 34.64 35.49 36.88 93.22 111.76 123.96 193.61
Lvivska 3.93 23.37 26.70 29.88 30.62 31.81 80.42 96.42 106.94 167.02
Kirovohradska 4.22 25.11 28.69 32.11 32.90 34.19 86.43 103.61 114.92 179.49
Kyivska 5.10 30.38 34.70 38.84 39.80 41.35 104.54 125.33 139.01 217.10
Ivano- 
Frankivska 4.01 23.89 27.30 30.56 31.31 32.53 82.23 98.59 109.35 170.78
Zaporizka 3.97 23.64 27.01 30.23 30.98 32.19 81.36 97.55 108.19 168.98
Zakarpatska 4.64 27.59 31.52 35.29 36.15 37.56 94.96 113.85 126.27 197.22
Zhytomyrska 4.58 27.23 31.11 34.82 35.68 37.07 93.72 112.36 124.63 194.64
Dnipro- 
petrovska 4.61 27.46 31.37 35.11 35.97 37.38 94.49 113.28 125.65 196.23
Volynska 3.98 23.70 27.08 30.31 31.05 32.27 81.56 97.79 108.46 169.39
Vinnytska 3.31 19.73 22.54 25.22 25.84 26.85 67.88 81.38 90.27 140.98
Note:  – Group І 1.89–76.38 USD;  – Group ІІ 76.39–150.87 USD;  – Group ІІІ 150.88–225.36 USD
Among the medicines included in the program “Available medicines” the lowest indicator is 
for Hydrochlorothiazide, 25 mg, No.20, in the Khersonska region both in 2019 and in 2020 – 11.24 
and 8.08 USD, respectively. The highest indicator is for Clopidogrel, 75 mg, No. 90 – 144.29 and 
135.09 USD in the Mykolaivska region. 
In particular, both in 2019 and in 2020 the lowest indicator of consumption of all drugs stud-
ied is in the Khersonska region, and the highest indicator is in the Mykolaivska region. There is also 
an uneven consumption of medicines involved in the program among the regions of Ukraine. This 
is due to the fact that the uneven number of pharmacies participating in the program by regions of 
the country is involved.
Taking into account the further prospect of expanding the government program it should be 
noted that Acetylsalicylic acid is an affordable, effective and safe antiplatelet agent in the treatment 
of CVD and is included in the list of essential drugs recommended by the WHO in the doses of 
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500 and 100 mg. Therefore, its inclusion in the list of the drugs reimbursed is an effective step 
towards improving pharmaceutical care for patients with CVD. 
Table 5
The overall average indicators of forecasting drug reimbursement cost in the regions of Ukraine per one 
patient in 2020 (USD)
Drug 
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Khersonska 1.36 8.08 9.24 10.34 10.59 11.01 27.82 33.36 37.00 57.78
Vinnytska 3.15 18.77 21.45 24.00 24.59 25.55 64.60 77.45 85.90 134.16
Cherkaska 3.50 20.85 23.82 26.66 27.31 28.38 71.74 86.01 95.40 148.99
Kharkivska 3.62 21.54 24.61 27.54 28.22 29.32 74.13 88.87 98.57 153.95
Lvivska 3.69 21.98 25.11 28.11 28.80 29.92 75.65 90.69 100.59 157.10
Odeska 3.84 22.86 26.12 29.23 29.95 31.12 78.67 94.32 104.61 163.38
Zaporizka 3.89 23.16 26.46 29.62 30.35 31.53 79.71 95.56 106.00 165.55
Chernivetska 3.91 23.27 26.59 29.76 30.49 31.68 80.09 96.02 106.50 166.34
Volynska 3.92 23.32 26.64 29.82 30.55 31.74 80.24 96.20 106.70 166.65
Chernihivska 3.94 23.43 26.76 29.96 30.69 31.89 80.62 96.65 107.20 167.43
Ivano- 
Frankivska 3.99 23.75 27.14 30.38 31.12 32.34 81.75 98.01 108.71 169.78
Rivnenska 4.00 23.81 27.20 30.45 31.19 32.41 81.94 98.23 108.95 170.16
Kirovohradska 4.09 24.36 27.83 31.15 31.92 33.16 83.84 100.51 111.48 174.12
Khmelnytska 4.18 24.86 28.40 31.79 32.57 33.84 85.55 102.56 113.76 177.66
Sumska 4.37 26.03 29.74 33.29 34.10 35.44 89.58 107.40 119.12 186.04
Zakarpatska 4.53 26.94 30.78 34.45 35.29 36.67 92.70 111.14 123.27 192.53
City of Kyiv 4.56 27.14 31.01 34.71 35.56 36.95 93.41 111.98 124.21 193.99
Poltavska 4.59 27.33 31.22 34.95 35.81 37.21 94.06 112.76 125.07 195.34
Dnipro- 
petrovska 4.64 27.64 31.58 35.35 36.22 37.63 95.13 114.05 126.50 197.57
Ternopilska 4.70 27.96 31.94 35.75 36.63 38.06 96.21 115.34 127.94 199.81
Zhytomyrska 4.71 28.02 32.01 35.83 36.71 38.14 96.42 115.59 128.21 200.24
Kyivska 4.79 28.50 32.56 36.44 37.34 38.80 98.08 117.58 130.41 203.68
Mykolaivska 4.96 29.52 33.73 37.75 38.68 40.19 101.59 121.80 135.09 210.99
Note:  – Group І 1.36–71.23 USD;  – Group ІІ 71.24–141.11USD;  – Group ІІІ 141.12–210.99 USD
For 2019 the forecasting amount of drug reimbursement for Clopidogrel is 12108.13 USD thou-
sand, and for Acetylsalicylic acid (in case of its inclusion in the program) it is 444.55 USD thousand, 
therefore, it is 11663,57 USD thousand (by 27.24 %) less. For example, if a physician prescribes medi-
cines containing acetylsalicylic acid to patients (if the medicine is well tolerated), instead of Clopido-
grel, the state will be able to distribute and save budget funds more rationally [11, 12].
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5. Discussion
Improvement and provision of high-quality and affordable care to patients with socially 
important pathologies is a priority in development and formation of an effective healthcare sys-
tem [13]. The study of decision-making in drug reimbursement author of the inventory increase 
spending on health in the world and part reimbursement mechanisms in public policy [14]. Author 
Johnson P.E. in his work «Pharmaceutical reimbursement: an overview» describes the benefits 
of electronic information programs for the health system and their participation in the process of 
reimbursement of the cost of medicines [15]. In their work «Pharmaceutical pricing and reimburse-
ment in China» scientists emphasize that regulation of the healthcare system is necessary to ensure 
transparency at all stages of decision making and, as a consequence, rationalization of all processes 
to improve the quality standards of treatment [16].
For example, in the study «Health Care Economics: The Real Source of Reimburse-
ment Problems» the author describes the problems faced by the healthcare system in the UK 
when reimbursing the cost of services to patients [17]. As a variant to solve the problem the 
author offers new models for reimbursement of services used by the patient in the process of 
treatment.
In another study «Evolution of drug reimbursement in Canada: The Pan-Canadian pharma-
ceutical alliance for new drugs», the authors noted that public authorities, medical and pharmaceu-
tical workers, patients and other participants involved in the process of providing care to patients 
need to improve mechanisms for reimbursement of drugs and services through negotiations, as 
well as a clear definition of duties and obligations for all participants [18]. The authors of the article 
«The future of cardiovascular care: From affordable care to the academic medical center» identified 
problems in the healthcare system of America associated with budgetary costs for patients. Spend-
ing on programs to provide CVD patients with medical and pharmaceutical care is increasing, 
and therefore, it is necessary to redistribute risks and pay more attention to optimizing the cost of 
services [19, 20].
In Ukraine, forecasting the indicators for drug reimbursement is performed for the first 
time for patients with CVD within the framework of the government program and is of significant 
importance in the further process of reforming and developing the healthcare system. Thanks to 
the prognosis and possible further expansion of the program “Available medicines” for drug reim-
bursement patients with CVD will be able to get help.
6. Conclusion
1. CVD is the leading cause of premature mortality among the world’s working-age popu-
lation. The high prevalence and subsequent mortality from CVD are due to a number of factors, 
including heredity, concomitant diseases, ecology, inadequate therapy and low solvency of the 
population.
2. According to the results for forecasting the volume of drug reimbursement to patients with 
CVD under the government program it has been found that Clopidogrelhas the 12108.13 USD thou-
sand and 11908.24 USD Thousand, Enalaprilthe takes second position – 1 highest indicator – 
10916.4 USD thousand in 2019 and 10736.18 USD thousand in 2020, while Amlodipine occupies 
the third position – 9105.60 USD Thousand and 8955.28 USD thousand. 
3. Among the medicines not included in the government program the largest forecast-
ing amount required for reimbursement (in case of inclusion in the program) is 18910.55 USD 
Thousand in 2019 and 18598.36 USD Thousand in 2020 for Magnicor, and the least amount is 
444.55 USD Thousand and 437.22 USD Thousand for Acetylsalicylic acid, respectively.
4. Despite the fact that the treatment with Acetylsalicylic acid should be carried out on a 
regular basis in patients with hypertension and coronary artery disease, it is necessary to include 
this medicine or its analogs in accordance with clinical protocols and international standards of 
treatment to the program “Available medicines”. The inclusion of medicines of Acetylsalicylic acid 
in the reimbursement program will make it possible to reduce morbidity and mortality from CVD, 
as well as guarantee access to high-quality and effective pharmacotherapy for all segments of the 
population.
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